US 12,377,042 B2
Botanical and bacterial extracts displaying retinol-like activity
Wen-Hwa Li, Cranbury, NJ (US); Khalid Mahmood, Lawrenceville, NJ (US); Ramine Parsa, Lawrenceville, NJ (US); Daphne Meza, Hillsborough, NJ (US); Antonius Pieter J. Van Den Heuvel, Willow Grove, PA (US); Teena Varghese, Philadelphia, PA (US); and Marina Nelen, Medford, MA (US)
Assigned to Kenvue Brands LLC, Summit, NJ (US)
Filed by KENVUE BRANDS LLC, Summit, NJ (US)
Filed on Aug. 3, 2023, as Appl. No. 18/229,995.
Application 18/229,995 is a continuation of application No. 16/519,207, filed on Jul. 23, 2019.
Claims priority of provisional application 62/703,903, filed on Jul. 27, 2018.
Prior Publication US 2023/0381075 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 8/37 (2006.01); A61K 8/36 (2006.01); A61K 8/9789 (2017.01); A61K 8/99 (2017.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 35/74 (2015.01); A61K 36/28 (2006.01); A61K 36/48 (2006.01); A61K 36/54 (2006.01); A61K 36/75 (2006.01); A61P 17/10 (2006.01); A61Q 17/00 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 8/9789 (2017.08) [A61K 8/361 (2013.01); A61K 8/37 (2013.01); A61K 8/99 (2013.01); A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 35/74 (2013.01); A61K 36/28 (2013.01); A61K 36/48 (2013.01); A61K 36/54 (2013.01); A61K 36/75 (2013.01); A61P 17/10 (2018.01); A61Q 17/00 (2013.01); A61Q 19/08 (2013.01); A61K 2800/30 (2013.01); A61K 2800/75 (2013.01)] 19 Claims
 
1. A method, comprising:
identifying skin with the presence of lines and wrinkles and/or loss of elasticity due to diminished synthesis of collagen or elastin,
topically applying to the skin a composition comprising a vehicle and a safe and effective amount of an agent that is 3-(4-farnesyloxyphenyl)-propionic acid and/or an ethyl ester thereof to elicit retinol-like bioactivity, and
wherein the application of the agent to the skin upregulates at least one of:
(a) cellular retinoic acid binding protein-II (CRAPB2),
(b) hyaluronic acid synthase 3 (HAS3),
(c) heparin-binding epidermal growth factor (HbEGF), or
(d) UDP-glucose ceramide glucosyltransferase (UGCG), on the order of a 0.1% retinol composition.